Acurx says FDA signaled NDA could hinge on totality of data

Acurx Pharmaceuticals (NASDAQ:ACXP) said the FDA signaled an NDA could rest on the totality of data, potentially including a single robust Phase 3, with planned rCDI trial results adding support. The company also cited in vitro co-culture work showing ibezapolstat outperformed vancomycin and fidaxomicin against C. difficile/C. difficile-related targets.